Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate
Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-ch...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
|
| Series: | Brazilian Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000600007&lng=en&tlng=en |
| _version_ | 1818127346436145152 |
|---|---|
| author | Bruno Caramelli Claudia Y.S.M. de Bernoche Ana M. C. Sartori Andrei C. Sposito Raul D. Santos Maristela C. Monachini Tania Strabelli Davi Uip |
| author_facet | Bruno Caramelli Claudia Y.S.M. de Bernoche Ana M. C. Sartori Andrei C. Sposito Raul D. Santos Maristela C. Monachini Tania Strabelli Davi Uip |
| author_sort | Bruno Caramelli |
| collection | DOAJ |
| description | Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-cholesterol, triglycerides (TG), and CD4+ T-cell counts were measured in 30 HAART-naive patients (Group I) before and after PI introduction. In a second phase of the study, the effects of fenofibrate on lipids, CPK, CD4+, and viral load were determined in 13 patients (Group II) with elevated TC or TG. In Group I, 60% of the patients showed TC or TG elevations. Average increments of 31% and 146% in TC and TG respectively (p<0.0006 and p<0.0001) were observed. In Group II, fenofibrate treatment was associated with decrements of 6.6% (TC) and 45.7% (TG) (p=0.07 and 0.0002) and no modifications on CPK, CD4+, and viral load. In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment. |
| first_indexed | 2024-12-11T07:15:54Z |
| format | Article |
| id | doaj.art-6ed92e8bc6d14115a95dd22febe1233b |
| institution | Directory Open Access Journal |
| issn | 1678-4391 |
| language | English |
| last_indexed | 2024-12-11T07:15:54Z |
| publisher | Elsevier |
| record_format | Article |
| series | Brazilian Journal of Infectious Diseases |
| spelling | doaj.art-6ed92e8bc6d14115a95dd22febe1233b2022-12-22T01:16:13ZengElsevierBrazilian Journal of Infectious Diseases1678-43915633233810.1590/S1413-86702001000600007S1413-86702001000600007Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrateBruno Caramelli0Claudia Y.S.M. de Bernoche1Ana M. C. Sartori2Andrei C. Sposito3Raul D. Santos4Maristela C. Monachini5Tania Strabelli6Davi Uip7Universidade de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloUniversidade de São PauloHyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-cholesterol, triglycerides (TG), and CD4+ T-cell counts were measured in 30 HAART-naive patients (Group I) before and after PI introduction. In a second phase of the study, the effects of fenofibrate on lipids, CPK, CD4+, and viral load were determined in 13 patients (Group II) with elevated TC or TG. In Group I, 60% of the patients showed TC or TG elevations. Average increments of 31% and 146% in TC and TG respectively (p<0.0006 and p<0.0001) were observed. In Group II, fenofibrate treatment was associated with decrements of 6.6% (TC) and 45.7% (TG) (p=0.07 and 0.0002) and no modifications on CPK, CD4+, and viral load. In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000600007&lng=en&tlng=enCholesterollipidsHIV infectiontriglycerides |
| spellingShingle | Bruno Caramelli Claudia Y.S.M. de Bernoche Ana M. C. Sartori Andrei C. Sposito Raul D. Santos Maristela C. Monachini Tania Strabelli Davi Uip Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate Brazilian Journal of Infectious Diseases Cholesterol lipids HIV infection triglycerides |
| title | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate |
| title_full | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate |
| title_fullStr | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate |
| title_full_unstemmed | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate |
| title_short | Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate |
| title_sort | hyperlipidemia related to the use of hiv protease inhibitors natural history and results of treatment with fenofibrate |
| topic | Cholesterol lipids HIV infection triglycerides |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000600007&lng=en&tlng=en |
| work_keys_str_mv | AT brunocaramelli hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT claudiaysmdebernoche hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT anamcsartori hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT andreicsposito hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT rauldsantos hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT maristelacmonachini hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT taniastrabelli hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate AT daviuip hyperlipidemiarelatedtotheuseofhivproteaseinhibitorsnaturalhistoryandresultsoftreatmentwithfenofibrate |